Telix opens Australian-first radiopharmaceutical facility

MELBOURNE, Australia, July 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia's capability in one of the world's fastest-growing areas of cancer diagnosis and treatment.

Telix Manufacturing Solutions North Melbourne (TMSNM) is a purpose-built site that combines radiochemistry laboratories, clinical product manufacturing, patient dose administration and imaging. It is a first-of-its-kind Australian facility that integrates these capabilities at a single location. The facility will help address manufacturing capacity constraints and the need to make and administer radiopharmaceutical doses in close proximity to patients. It will link research, clinical trials and treatment, and is intended to significantly reduce the timeframe from early-stage trials to broad patient access.

Patient care and research at the site will be delivered by the Melbourne Theranostic Innovation Centre (MTIC), overseen by world-leading nuclear medicine clinician-researcher Professor Rod Hicks. The Telix and MTIC clinical research collaboration covers Telix-sponsored studies, investigator-initiated trials and select third party collaborations.

Dr. Christian Behrenbruch, Telix Managing Director and Group CEO, commented, "Radiopharmaceuticals are fast becoming an important part of cancer care, but manufacturing capacity for novel treatments, which needs to be near patients, remains a constraint in Australia. This facility will allow us to move new treatments from research into the clinic and patient use more efficiently. It is also an investment in Australia's sovereign manufacturing capability and the specialist workforce needed to build a globally competitive radiopharmaceutical industry."

Professor Rod Hicks, MTIC Founder, Chair and Chief Medical Officer, added, "Bringing these capabilities together will give clinicians faster access to novel radiopharmaceuticals and allow emerging technologies to be assessed in a real-world clinical setting. It will help us select patients more precisely, measure treatment response and generate evidence more quickly as we evaluate new targets and next generation isotopes and treatment approaches."

Radiopharmaceuticals that can reveal the location of tumors on scans and deliver therapeutic radiation directly to cancer cells are rapidly emerging as the 'sixth pillar' of cancer care, alongside surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy.

TMSNM will also support training in nuclear medicine, radiochemistry, engineering and clinical research, helping develop the specialist workforce required by Australia's health and life sciences sector.

For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.